Tag

AstraZeneca

11 stories

Deals Jul 6, 2026

Novartis Buys Myricx for $1.1B in ADC Push

Novartis just paid $1.1B for a biotech whose lead drugs have never touched a human patient. The math on that bet doesn't look cheap.

Deals Jul 3, 2026

AstraZeneca Pays CSPC $30M for $1.77B Kidney Deal

AstraZeneca puts just $30M down now to control up to $1.77B in kidney-drug milestones, its fourth check written to Chinese partner CSPC since 2024.

Legal Jun 30, 2026

Paid Up: AstraZeneca's $34M Kickback Settlement

AstraZeneca just became Ken Paxton's latest pharma kickback target, paying nearly $34M for 'free nurses' without admitting wrongdoing.

Deals Jun 22, 2026

Nuvectis Buys Haisco Factor B Rights for $40M

Nuvectis paid $40M upfront for ex-China rights to Haisco's once-daily Factor B inhibitor in a PNH market projected above $5B in 2026.

FDA May 4, 2026

Celcuity Beats Piqray in Phase 3, Shares Jump 15%

Pfizer sold gedatolisib to Celcuity for $10 million upfront in 2021.

FDA Apr 20, 2026

Wins Third Phase 3 in COPD: AstraZeneca's Tozorakimab Eyes $5B Peak

Tozorakimab now has three phase 3 COPD wins in 2026.

Deals Apr 16, 2026

Cleared $22B: Q1 2026 Obesity Deals Top 2025's Full-Year Total

Biopharma committed $22 billion to obesity and diabetes licensing deals in Q1 2026, clearing last year's full-year total of $20.3 billion with three…

FDA Apr 13, 2026

Beats Venetoclax: Lilly's Jaypirca Posts 4th Phase 3 Win in CLL

Jaypirca chalked up its fourth positive phase 3 readout in chronic lymphocytic leukemia on Monday, and this one rewrites the treatment calculus: it's the…

Deals Apr 13, 2026

Regeneron Paid $40M to Enter Radiopharma; Telix Scores Up to $4.3B

Regeneron put $40 million on the table Sunday to partner with Telix Pharmaceuticals, the Australian biotech with one of the more active radiopharmaceutical…

Deals Apr 5, 2026

Syneron Bio Pulls $150M Series B Four Months After $100M Round

Syneron Bio raises $150M Series B, bringing total funding to $250M in four months, backed by AstraZeneca and Abu Dhabi sovereign wealth.

Deals Apr 5, 2026

Lilly Pays $115M Upfront in Insilico AI Deal Worth Up to $2.75B

Eli Lilly paid $115M upfront for an AI collaboration with Insilico Medicine worth up to $2.75B, with milestone math that heavily favors Lilly.